Metastatic chromophobe renal cell carcinoma treated with targeted therapies: a Renal Cross Channel Group study

Emeline Colomba, Gwénaël Le Teuff, Tim Eisen, Grant D. Stewart, Kate Fife, James Larkin, Andrea Biondo, Lisa Pickering, Anandagopal Srinivasan, Helen Boyle, Lisa Derosa, Cora N. Sternberg, Federica Recine, Christy Ralph, Carolina Saldana, Philippe Barthélémy, Jean Christophe Bernhard, Howard Gurney, Gregory Verhoest, Elodie Vauleon & 11 others Pierre Bigot, Julien Berger, Christian Pfister, Gwenaelle Gravis, Jean-Michel Rodier, Stéphane Culine, Armelle Caty, Frederic Rolland, Franck Priou, Bernard Escudier, Laurence Albiges

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Treatment of non–clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC. Methods: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan–Meier method. Results: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0–13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4–46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2–10.9) and 22.9 months (95% CI: 17.8–49.2) versus 1.9 months (95% CI: 1.0–6.0) and 3.2 months (95% CI: 2.3–not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55). Conclusion: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.

LanguageEnglish
Pages55-62
Number of pages8
JournalEuropean Journal of Cancer
Volume80
DOIs
Publication statusPublished - 1 Jul 2017

Fingerprint

Sirolimus
Renal Cell Carcinoma
Treatment Failure
Kidney
Confidence Intervals
Survival
Therapeutics
Vascular Endothelial Growth Factor A
Databases
Prospective Studies
Neoplasm Metastasis

Keywords

  • non–clear cell RCC
  • chromophobe RCC
  • metastatic
  • anti-angiogenic
  • VEGF
  • mTOR

Cite this

Colomba, Emeline ; Le Teuff, Gwénaël ; Eisen, Tim ; Stewart, Grant D. ; Fife, Kate ; Larkin, James ; Biondo, Andrea ; Pickering, Lisa ; Srinivasan, Anandagopal ; Boyle, Helen ; Derosa, Lisa ; Sternberg, Cora N. ; Recine, Federica ; Ralph, Christy ; Saldana, Carolina ; Barthélémy, Philippe ; Bernhard, Jean Christophe ; Gurney, Howard ; Verhoest, Gregory ; Vauleon, Elodie ; Bigot, Pierre ; Berger, Julien ; Pfister, Christian ; Gravis, Gwenaelle ; Rodier, Jean-Michel ; Culine, Stéphane ; Caty, Armelle ; Rolland, Frederic ; Priou, Franck ; Escudier, Bernard ; Albiges, Laurence. / Metastatic chromophobe renal cell carcinoma treated with targeted therapies : a Renal Cross Channel Group study. In: European Journal of Cancer. 2017 ; Vol. 80. pp. 55-62.
@article{0479fe7d2d754e98a57da8728d2c3d7b,
title = "Metastatic chromophobe renal cell carcinoma treated with targeted therapies: a Renal Cross Channel Group study",
abstract = "Background: Treatment of non–clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC. Methods: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan–Meier method. Results: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0–13.9). Median OS was 37.9 months (95{\%} confidence interval [CI]: 21.4–46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82{\%}) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95{\%} CI: 5.2–10.9) and 22.9 months (95{\%} CI: 17.8–49.2) versus 1.9 months (95{\%} CI: 1.0–6.0) and 3.2 months (95{\%} CI: 2.3–not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55). Conclusion: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.",
keywords = "non–clear cell RCC, chromophobe RCC, metastatic, anti-angiogenic, VEGF, mTOR",
author = "Emeline Colomba and {Le Teuff}, Gw{\'e}na{\"e}l and Tim Eisen and Stewart, {Grant D.} and Kate Fife and James Larkin and Andrea Biondo and Lisa Pickering and Anandagopal Srinivasan and Helen Boyle and Lisa Derosa and Sternberg, {Cora N.} and Federica Recine and Christy Ralph and Carolina Saldana and Philippe Barth{\'e}l{\'e}my and Bernhard, {Jean Christophe} and Howard Gurney and Gregory Verhoest and Elodie Vauleon and Pierre Bigot and Julien Berger and Christian Pfister and Gwenaelle Gravis and Jean-Michel Rodier and St{\'e}phane Culine and Armelle Caty and Frederic Rolland and Franck Priou and Bernard Escudier and Laurence Albiges",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.ejca.2017.03.011",
language = "English",
volume = "80",
pages = "55--62",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Pergamon Press",

}

Colomba, E, Le Teuff, G, Eisen, T, Stewart, GD, Fife, K, Larkin, J, Biondo, A, Pickering, L, Srinivasan, A, Boyle, H, Derosa, L, Sternberg, CN, Recine, F, Ralph, C, Saldana, C, Barthélémy, P, Bernhard, JC, Gurney, H, Verhoest, G, Vauleon, E, Bigot, P, Berger, J, Pfister, C, Gravis, G, Rodier, J-M, Culine, S, Caty, A, Rolland, F, Priou, F, Escudier, B & Albiges, L 2017, 'Metastatic chromophobe renal cell carcinoma treated with targeted therapies: a Renal Cross Channel Group study', European Journal of Cancer, vol. 80, pp. 55-62. https://doi.org/10.1016/j.ejca.2017.03.011

Metastatic chromophobe renal cell carcinoma treated with targeted therapies : a Renal Cross Channel Group study. / Colomba, Emeline; Le Teuff, Gwénaël; Eisen, Tim; Stewart, Grant D.; Fife, Kate; Larkin, James; Biondo, Andrea; Pickering, Lisa; Srinivasan, Anandagopal; Boyle, Helen; Derosa, Lisa; Sternberg, Cora N.; Recine, Federica; Ralph, Christy; Saldana, Carolina; Barthélémy, Philippe; Bernhard, Jean Christophe; Gurney, Howard; Verhoest, Gregory; Vauleon, Elodie; Bigot, Pierre; Berger, Julien; Pfister, Christian; Gravis, Gwenaelle; Rodier, Jean-Michel; Culine, Stéphane; Caty, Armelle; Rolland, Frederic; Priou, Franck; Escudier, Bernard; Albiges, Laurence.

In: European Journal of Cancer, Vol. 80, 01.07.2017, p. 55-62.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Metastatic chromophobe renal cell carcinoma treated with targeted therapies

T2 - European Journal of Cancer

AU - Colomba, Emeline

AU - Le Teuff, Gwénaël

AU - Eisen, Tim

AU - Stewart, Grant D.

AU - Fife, Kate

AU - Larkin, James

AU - Biondo, Andrea

AU - Pickering, Lisa

AU - Srinivasan, Anandagopal

AU - Boyle, Helen

AU - Derosa, Lisa

AU - Sternberg, Cora N.

AU - Recine, Federica

AU - Ralph, Christy

AU - Saldana, Carolina

AU - Barthélémy, Philippe

AU - Bernhard, Jean Christophe

AU - Gurney, Howard

AU - Verhoest, Gregory

AU - Vauleon, Elodie

AU - Bigot, Pierre

AU - Berger, Julien

AU - Pfister, Christian

AU - Gravis, Gwenaelle

AU - Rodier, Jean-Michel

AU - Culine, Stéphane

AU - Caty, Armelle

AU - Rolland, Frederic

AU - Priou, Franck

AU - Escudier, Bernard

AU - Albiges, Laurence

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background: Treatment of non–clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC. Methods: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan–Meier method. Results: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0–13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4–46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2–10.9) and 22.9 months (95% CI: 17.8–49.2) versus 1.9 months (95% CI: 1.0–6.0) and 3.2 months (95% CI: 2.3–not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55). Conclusion: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.

AB - Background: Treatment of non–clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC. Methods: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan–Meier method. Results: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0–13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4–46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2–10.9) and 22.9 months (95% CI: 17.8–49.2) versus 1.9 months (95% CI: 1.0–6.0) and 3.2 months (95% CI: 2.3–not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55). Conclusion: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.

KW - non–clear cell RCC

KW - chromophobe RCC

KW - metastatic

KW - anti-angiogenic

KW - VEGF

KW - mTOR

UR - http://www.scopus.com/inward/record.url?scp=85019953522&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2017.03.011

DO - 10.1016/j.ejca.2017.03.011

M3 - Article

VL - 80

SP - 55

EP - 62

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -